title: Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
abstract: OBJECTIVE
  To evaluate the safety and hematologic tolerance of 2'-3'-dideoxyinosine (didanosine, ddI) in subjects with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and prior hematologic intolerance to zidovudine.
  
  
  METHODS
  A Phase I trial with two dose groups at a single-center, university-affiliated hospital ambulatory care center. Of 30 subjects enrolled, 21 had AIDS and nine had AIDS-related complex. All had CD4 lymphocyte counts less than 0.2 x 10(9)/L at entry. Didanosine was administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks. Subjects who completed the 12-week study continued to receive ddI at the lower dose. All subjects were monitored for toxicity. Virologic and immunologic response markers were also measured.
  
  
  RESULTS
  For the group as a whole, there was no significant decrease in mean hemoglobin level or leukocyte or platelet counts. The dose-limiting toxicity was peripheral neuropathy. Other significant toxicities included pancreatitis and hypocalcemia. Uric acid elevations were common but were without clinical consequence. A sustained decrease in serum p24 antigen of at least 50% was noted in 42% of subjects who were p24 antigen-positive at entry. The mean CD4 lymphocyte count showed an initial increase that was not sustained over the 12-week study. All subjects remained anergic to skin testing.
  
  
  CONCLUSIONS
  Didanosine is well tolerated hematologically in some patients with prior significant hematologic intolerance to zidovudine. The toxicity profile for ddI differs from that of zidovudine and includes peripheral neuropathy and pancreatitis. Changes in CD4 lymphocyte number and HIV p24 antigen levels in some patients suggest antiviral activity of ddI in this population.
authors.affiliation: Section of Infectious Disease, New England Deaconess Hospital, Boston, Massachusetts.
authors.forename: K J
authors.initials: KJ
authors.lastname: Connolly
authors.forename: J D
authors.initials: JD
authors.lastname: Allan
authors.forename: H
authors.initials: H
authors.lastname: Fitch
authors.forename: L
authors.initials: L
authors.lastname: Jackson-Pope
authors.forename: C
authors.initials: C
authors.lastname: McLaren
authors.forename: R
authors.initials: R
authors.lastname: Canetta
authors.forename: J E
authors.initials: JE
authors.lastname: Groopman
mesh_terms: D000386:AIDS-Related Complex / Q000097:blood / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy*; D000284:Administration, Oral; D000328:Adult; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D015215:Zidovudine / Q000009:adverse effects
chemical_list: D006454:Hemoglobins; D015215:Zidovudine; D016049:Didanosine